Navigation Links
Results of the COBRA trial reported at TCT 2011
Date:11/11/2011

SAN FRANCISCO, CA NOVEMBER 11, 2011 A clinical trial of patients with diabetes has demonstrated that cryoplasty post-dilitation compared to conventional balloon angioplasty in the superficial femoral artery (SFA) decreased the risk of in-stent restenosis (ISR). Results from the COBRA clinical trial were presented today at the 23rd Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

Diabetes is associated with increased risk of in-stent restenosis after superficial femoral artery (SFA) stenting with nitinol self-expanding stents (nSES). The objective of the COBRA trial (Cryoplasty Or Conventional Balloon Post-dilation of Nitinol Stents For Revascularization of Peripheral Arterial Segments) was to determine whether cryoplasty post-dilation, when compared to conventional balloon angioplasty, decreases the risk of SFA nSES in-stent restenosis.

Researchers used a cryoplasty dilatation system that simultaneously dilates and cools the vessel wall. Cooling to -10oC was achieved by inflating the balloon with nitrous oxide instead of saline and contrast. The system induces smooth muscle cell (SMC) apoptosis, minimizes SMC necrosis (-5 to -15oC) and reduces ISR.

In this prospective, multi-center, randomized clinical trial, 121 patients with diabetes mellitus were enrolled between August 2008 and December 2010 in four clinical sites within the United States. Inclusion criteria included insulin or non-insulin dependent diabetic patients, severe lifestyle limiting claudication (Rutherford category ≥3), chronic critical limb ischemia with rest pain (RB stage 4) or ischemic ulcers (RB stage 5), and SFA lesions requiring nSES ≥5 mm in diameter and ≥60mm in length.

Seventy-four patients with 90 SFA lesions were randomized to cryoplasty (n=45 lesions) or conventional balloon angioplasty (CBA) (n=45 lesions). Mean age was 6411.4 years, and 88% were men. Mean hemoglobin A1C was 7.41.6 g/dL. The baseline ankle-brachial index (ABI) was 0.590.21 and 0.620.19 in the cryoplasty and CBA groups, respectively.

The primary endpoint was 12 month SFA nSES binary in-segment restenosis, defined as a ≥2.5 times increase in peak systolic velocity by duplex ultrasound. The rate of occurrence was 55.8% for the conventional balloon group and 29.3% for the cryoplasty group.

"In patients with diabetes mellitus presenting with life-style limiting claudication, post-dilation of nitinol self-expanding stents in the superficial femoral artery using cryoplasty significantly reduced 12-month in-stent restenosis compared to conventional balloon post-dilation," said Subhash Banerjee MD. Dr. Banerjee is Chief of Division of Cardiology at VA North Texas Health Care and Associate Professor of Medicine at The University of Texas Southwestern Medical Center in Dallas, Texas.

"These results indicate the potential impact of stent post-dilation strategies on endovascular treatment of symptomatic peripheral arterial disease," Dr. Banerjee said.


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Results of the PROFI study reported at TCT 2011
2. Results of the EVOLVE trial reported at TCT 2011
3. Results of the REMEDEE trial reported at TCT 2011
4. Results of the NEXT clinical trial Reported at TCT 2011
5. Results of the PEPCAD-DES trial reported at TCT 2011
6. Results of the STACCATO Trial reported at TCT 2011
7. Results of the DEB-AMI Trial reported at TCT 2011
8. Results of the RIFLE STEACS clinical trial reported at TCT 2011
9. Results of the PARTNER Trial Cohort B 2-year follow up presented at TCT 2011
10. Results of the PARTNER Trial Cohort A cost effectiveness analysis reported
11. Combination epigenetic therapy clinical trial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... ... (BIAA) is collaborating with a New England student to educate the public on ... acclaim in 2016 for launching the first-ever National Concussion Awareness Day. , Brooke ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... recently launched community enrichment program. Partnering once again with Boys & Girls Clubs ... to help find the area’s very own American Idol. With all proceeds benefitting ...
(Date:8/16/2017)... ... , ... LabRoots , the leading provider of educational and interactive virtual ... announce Andrew Ly as the winner of the LabRoots Summer Textbook scholarship, awarding him ... who is in his third year at the University of California, Los Angeles majoring ...
(Date:8/16/2017)... ... 2017 , ... Melbourne’s reign as the world’s most liveable city has been ... Liveability Index. , The Index surveys 140 of the world’s cities and Melbourne has ... consistently come in the top three of the index. So what is it that ...
(Date:8/16/2017)... ... August 16, 2017 , ... Connexion Point, a technology-enabled healthcare services company ... fourth consecutive year. With 197% revenue growth over the past three years, ... growing companies. , Previous honors include ranking 86th on the Inc. 500 ...
Breaking Medicine News(10 mins):
(Date:7/27/2017)... 2017  West Pharmaceutical Services, Inc. (NYSE: ... second-quarter 2017 and updated financial guidance for the full-year ... Highlights Reported net sales of $397.6 ... quarter. Net sales at constant currency (organic) grew by ... $0.51, compared to $0.60 in the prior-year quarter. Second-quarter ...
(Date:7/26/2017)... Sancilio Pharmaceuticals Company, Inc. (SPCI) today announced ... Altemia TM , an oral therapy for pediatric patients ... (SCD). The SCOT Trial, is a double-blind, placebo-controlled, dose-finding, ... Altemia TM in pediatric patients aged 5-17 years ... "The completion of ...
(Date:7/25/2017)... Fla. , July 25, 2017  Debbie,s Dream Foundation: Curing Stomach Cancer ... on Monday, September 25, 2017 at the Bonaventure Resort & Spa in ... ... DDF Founder and President Debbie Zelman, and Luncheon Committee Co-chair Sabrina Kurzman. ... Aura ...
Breaking Medicine Technology: